Buying low, Selling High
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No worries, we had to tag top bband to keep pps going up!
Ur full of shit! I called for 68 and sold 58, then it went to 79
Ur the fool who said my 35 buy was bad, yet I flipped out at 58, now back for second helping and I have a huge appetite!!! Learn to trade OTC ya fool!
I don't remember, but after I did the funnymental analysis I came up with $2.27 potential, and I'm a chartist, did you see that post?
Red to Green REVERSAL potential here today!!!
Above .02 and no selling pressure! The path is free and clear to .06 imo
Re-loaded 44's just now!!! Ask at 52 is very telling!
Support is 112, it may be a buy there with 89 stop, but I feel this has gotten moldy, time for a fresh play imo. GLTA
Ummm, Pretty sure he sold out at .003, now .0182!!! Lol!
Home is .06-.15
NSAV Surpasses 1 Million Users on NSAVx.com CEX ExchangePress Release | 05/17/2024
Net Savings Link, Inc. (OTC: NSAV), a cryptocurrency, blockchain and digital asset technology company, announced today that it has exceeded its annual target of 1 million new users on the NSAVx.com CEX exchange https://nsavx.com/ . This remarkable achievement was reached within the first month of Q2 2024, propelled by a strategic partnership with MyAirDropAlert.com (MADA) https://www.myairdropalert.com/ .
Growth Highlights:
User Base Update: As of May 17, 2024, the NSAVx.com platform has registered 1,108,923 users.
Revised Projections: Originally set at 1 million by year-end, the 2024 goal has now been ambitiously revised to 2.5 million users.
Strategic Partnerships and Marketing Success: This surge in new user registrations is attributed to the effective joint marketing campaign with MyAirDropAlert.com, which has significantly amplified the platforms visibility and appeal within the digital asset community.
NSAV released the following statement, "Surpassing 500,000 users earlier this week was a significant milestone, but reaching over 1 million users has set a new benchmark. This achievement not only puts NSAV on the radar of industry leaders but also highlights the effective execution and growing impact of our strategies. Our digital presence is expanding, casting a spotlight on our teams success.
NSAV's vision is the establishment of a fully integrated technology company, which provides turnkey technological solutions to the cryptocurrency, blockchain and digital asset industries. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, financial services, advisory services and information technology.
For further information please contact NSAV at info@nsavholdinginc.com
The NSAV Centralized Cryptocurrency Exchange (CEX) website can be accessed at https://nsavx.com/
The AirdropX.co website can be accessed at https://www.airdropx.co/
The NSAVx Token website can be accessed at https://www.nsavxtoken.com/nsavx-token
The NSAVx Discord Server can be accessed at https://discord.com/invite/7Q2Vv5NmKd
The NSAV Twitter account can be accessed at https://twitter.com/nsav_tech
The NSAV corporate website can be accessed at http://nsavholdinginc.com
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
Contact
Net Savings Link, Inc.
info@nsavholdinginc.com
https://www.otcmarkets.com/stock/NSAV/news/NSAV-Surpasses-1-Million-Users-on-NSAVxcom-CEX-Exchange?id=440999
Upper Bband prob comes in at 174 tomorrow, should support pps imo
Up $27K today!!! So reminds me of how 2021 started out!
Price is in full force breakout now! It's going up as fast as it can! I like it! My cool 1/4 mill$ win at .06 doesn't seem so far away now! I added 49K at 186 today, holding 5,375,000...that's $537.50 a tick!
WHAT A WONDERFUL DAY!
I don't see that gap, I do see one .0589-.0594
525mill volume! OTC is back! Like 2021!
There it is! 16's!!! I called for 15's!
Yes! They are very transparent! They keep us informed all the way up! They know how to feed a rally! Feed your rally! FEED IT!!!
Support 172 held, now back up! Over .02 by eod!
Rear view mirror shows when NSAV runs, it runs strong for 3 weeks! This is week 1!!!
Yes! 3 closes over .02 means .06 comes next!
Dow hit 40K! Money continues to flow into markets from the 5% sidelines! Crypto and OTC gonna fly like 2021!!! Lol!
.0112 is the rising 50 day, it may be a trade with stop at 89...but I feel it's over here pretty much, I have no interest in buying, plus got all my money on the Crypto exchange with revenues play!
If it's a measuring gap then it predicts .028-.029 coming
Yesterday's Key Reversal day and gap filled today says to me we saw the top yesterday at 188
IDK, but top bband is now 146 and we tagged it at 145 lod, there is a gap 140-145 but as long as price keeps tagging the top bband the sky is the limit!
YW, everyone gonna make huge profits here, cept the guy who sold 30 here, Lol!
I know, I was just having fun with ya, but man what a day!
.0179!!!! Imagine selling at 30 then watching it trade 179! Lol! Ouch! That's gotta hurt! Shoulda used charts!
My 165 target this week surpassed!
Hi! Switcharoo today! Looks like i won the bet!
TSOI Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation
ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Stimulation of Mesenchymal Stem Cell Therapeutics Activities by Regulatory T Cells.”
The issued patent claims include:
“A method of inhibiting lung inflammation comprising: a) identifying a subject suffering from lung inflammation; b) administering a population of T regulatory cells in combination with a population of plastic adherent umbilical cord derived mesenchymal stem cells in an amount sufficient to reduce inflammation in said subject’s lungs.”
Therapeutic Solutions International owns a Phase III Investigational New Drug application for treatment of COVID-19. However, the Company is working on a new application for treating “all-cause” acute respiratory distress syndrome (ARDS) using the company’s patented JadiCell1, a true mesenchymal stem cell. Additionally, the Company has filed a Phase I/II clinical trial for COPD and possesses preclinical data for pulmonary fibrosis. All of these conditions are examples of lung inflammation.
“The claims issued today, in our opinion, capture the whole area of using a specific type of immune system cell, termed ‘T Regulatory Cells’ for enhancing activity of mesenchymal stem cells in all the major lung pathologies,” said Dr. Thomas Ichim, Board Member of TSOI and co-inventor of the patent. “We anticipate significant value in the current patent based on other companies working in the area of T regulatory cells. This is validated by the Regeneron-Sonoma Therapeutics2 and the Quell-AstraZeneca3 deals. It is nice to know that we own a potent piece of intellectual property that anyone hoping to enter this space will need to license.”
Dr. Ichim has a strong history of success in the area of biotechnology having taken his company Medistem from a 7 cent share price when he was made CEO to a sale at $1.35 to Intrexon, a NYSE traded company. Dr. Ichim’s lifetime of science, FDA clearances, and over 400 issued and published patents, have taken multiple companies to NASDAQ public listings.
“At Therapeutic Solutions International we are building a critical mass of clinical data, scientific discoveries, and patents4,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “We believe we are developing significant traction which will result in partnerships and co-development deals.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 https://patents.google.com/patent/US9803176B2/en?oq=9803176
2 https://www.fiercebiotech.com/biotech/sonoma-biotherapeutics-takes-big-bite-120m-regeneron-collab-tacking-five-new-targets
3 https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-signs-2-bln-agreement-with-quell-develop-cell-therapies-2023-06-09/
4 https://patents.justia.com/assignee/therapeutic-solutions-international-inc
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240516930973r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516930973/en/
Timothy G. Dixon
ir@tsoimail.com
Source: Therapeutic Solutions International, Inc.
© Copyright Business Wire 2024
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2863154
Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases
Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation
ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Stimulation of Mesenchymal Stem Cell Therapeutics Activities by Regulatory T Cells.”
The issued patent claims include:
“A method of inhibiting lung inflammation comprising: a) identifying a subject suffering from lung inflammation; b) administering a population of T regulatory cells in combination with a population of plastic adherent umbilical cord derived mesenchymal stem cells in an amount sufficient to reduce inflammation in said subject’s lungs.”
Therapeutic Solutions International owns a Phase III Investigational New Drug application for treatment of COVID-19. However, the Company is working on a new application for treating “all-cause” acute respiratory distress syndrome (ARDS) using the company’s patented JadiCell1, a true mesenchymal stem cell. Additionally, the Company has filed a Phase I/II clinical trial for COPD and possesses preclinical data for pulmonary fibrosis. All of these conditions are examples of lung inflammation.
“The claims issued today, in our opinion, capture the whole area of using a specific type of immune system cell, termed ‘T Regulatory Cells’ for enhancing activity of mesenchymal stem cells in all the major lung pathologies,” said Dr. Thomas Ichim, Board Member of TSOI and co-inventor of the patent. “We anticipate significant value in the current patent based on other companies working in the area of T regulatory cells. This is validated by the Regeneron-Sonoma Therapeutics2 and the Quell-AstraZeneca3 deals. It is nice to know that we own a potent piece of intellectual property that anyone hoping to enter this space will need to license.”
Dr. Ichim has a strong history of success in the area of biotechnology having taken his company Medistem from a 7 cent share price when he was made CEO to a sale at $1.35 to Intrexon, a NYSE traded company. Dr. Ichim’s lifetime of science, FDA clearances, and over 400 issued and published patents, have taken multiple companies to NASDAQ public listings.
“At Therapeutic Solutions International we are building a critical mass of clinical data, scientific discoveries, and patents4,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “We believe we are developing significant traction which will result in partnerships and co-development deals.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 https://patents.google.com/patent/US9803176B2/en?oq=9803176
2 https://www.fiercebiotech.com/biotech/sonoma-biotherapeutics-takes-big-bite-120m-regeneron-collab-tacking-five-new-targets
3 https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-signs-2-bln-agreement-with-quell-develop-cell-therapies-2023-06-09/
4 https://patents.justia.com/assignee/therapeutic-solutions-international-inc
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20240516930973r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516930973/en/
Timothy G. Dixon
ir@tsoimail.com
Source: Therapeutic Solutions International, Inc.
© Copyright Business Wire 2024
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2863154
Been asking myself the same question, chartwise been thinking 3 closes over .06 means .25-.30 coming. But after the blow out earnings $204Mill net gain is sending me to the drawing board lmk what you think of this:
1st Qtr gain 204Mill
2nd Qtr est. 275Mill
3rd Qtr est. 350Mill
4th Qtr est. 425Mill
-------------------------
Equals 1,254Mill Est Net gain for 2024
Divided by Unrestricted OS 6,631,162,564 equals .189 earnings per share, times say typical 12 PE equals $2.27 price target by funnymentals right?
Nope, not seeing the dip below .0112 on Ihub's intraday charting, I saw it on your link, but it's not showing to the side or below the board posts intraday chart, see below, also I remember watching price today and saw the lod change to .01, then .0084 lod flashed, so I clicked over to my new Schwab ToS L2 and did NOT see anything trading under .0119 like Ihub's intraday shows. So my conclusion is the trades down to .01 and 80's never made it to the exchange as Fidelity told me, those trades never made it to L2 on ToS nor Ihub's L2, that's why Ihub is NOT showing the dip at 10:58 to .0084 on their intraday chart below, this proves the MM'ers hold shares and do what they want in OTC land IMO